Cited by 402Virus-based gene therapy researchPoxvirus research and outbreaksBacterial Cancer Therapy

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

Kirn, David H., Thorne, Steve H.·2009·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Viruses have been engineered for cancer therapy in a variety of ways. Approaches include non-replicating gene therapy vectors, cancer vaccines and oncolytic viruses, but the clinical efficacy of these approaches has been limited by multiple factors. However, a new therapeutic class of oncolytic poxviruses has recently been developed that combines targeted and armed approaches for treating cancer. Initial preclinical and clinical results show that products from this therapeutic class can systemically target cancers in a highly selective and potent fashion using a multi-pronged mechanism of action.

Integrity signals

Registry

Crossref · 10.1038/nrc2545

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C.-H., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,980
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,639
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Lotze, M. T., & Tracey, K. J. (2005) · Nature reviews. Immunology · doi:10.1038/nri1594 · Cited by 2,490
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C. C., Horn, S. T., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,769
Self-citation
Untitled work
(1988) · World Health Organization eBooks · Cited by 1,574
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi, H., Charnsangavej, C., Faria, S., Macapinlac, H., Burgess, M., Patel, S. R., Chen, L. L., Podoloff, D., & Benjamin, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3049 · Cited by 1,508
Smallpox and its eradication
Elwood, J. M. (1989) · Journal of Epidemiology & Community Health · doi:10.1136/jech.43.1.92 · Cited by 1,412
A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer
Khuri, F. R., Nemunaitis, J. J., Ganly, I., Arseneau, J. C., Tannock, I. F., Romel, L., Gore, M. E., Ironside, J. A. D., MacDougall, R. H., Heise, C. C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,099
Self-citation
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival
Chang, H. Y., Nuyten, D. S. A., Sneddon, J. B., Hastie, T., Tibshirani, R., Sørlie, T., Dai, H., He, Y. D., van't Veer, L. J., Bartelink, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409462102 · Cited by 981
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
Heise, C. C., Sampson-Johannes, A., Williams, A., McCormick, F. P., Hoff, D. D. V., & Kirn, D. H. (1997) · Nature Medicine · doi:10.1038/nm0697-639 · Cited by 941
Self-citation
Stem Cells and Cancer: Two Faces of Eve
Clarke, M. F., & Fuller, M. T. (2006) · Cell · doi:10.1016/j.cell.2006.03.011 · Cited by 921
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.
Stojdl, D., Lichty, B., TENOEVER, B., Paterson, J., Power, A., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 894
Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas
Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D. G., & Martuza, R. L. (1995) · Nature Medicine · doi:10.1038/nm0995-938 · Cited by 823
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
Stojdl, D. F., Lichty, B. D., Knowles, S., Marius, R. M., Atkins, H. L., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 818
Vaccinia Virus Uses Macropinocytosis and Apoptotic Mimicry to Enter Host Cells
Mercer, J., & Helenius, A. (2008) · Science · doi:10.1126/science.1155164 · Cited by 788
In vivo magnetic resonance imaging of transgene expression
Weissleder, R., Moore, A. V., Mahmood, U., Bhorade, R. M., Benveniste, H., Chiocca, E. A., & Basilion, J. P. (2000) · Nature Medicine · doi:10.1038/73219 · Cited by 776
Reovirus Therapy of Tumors with Activated Ras Pathway
Coffey, M. C., Strong, J. E., Forsyth, P. A., & Lee, P. W. K. (1998) · Science · doi:10.1126/science.282.5392.1332 · Cited by 750
Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox
Rubartelli, A., & Lotze, M. T. (2007) · Trends in Immunology · doi:10.1016/j.it.2007.08.004 · Cited by 614
Human Effector and Memory CD8+ T Cell Responses to Smallpox and Yellow Fever Vaccines
Miller, J. D., van der Most, R. G., Akondy, R. S., Glidewell, J. T., Albott, S., Masopust, D., Murali-Krishna, K., Mahar, P. L., Edupuganti, S., Lalor, S., et al. (2008) · Immunity · doi:10.1016/j.immuni.2008.02.020 · Cited by 601
An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy
Heise, C. C., Hermiston, T. W., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L. K., & Kirn, D. H. (2000) · Nature Medicine · doi:10.1038/80474 · Cited by 584
Self-citation
A Phase I Study of OncoVEXGM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor
Hu, J. C. C., Coffin, R. S., Davis, C. J., Graham, N. J., Groves, N., GUEST, P. J., Harrington, K. J., James, N. D., Love, C., McNeish, I. A., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0759 · Cited by 571
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D. L., Forsyth, P. A., & Bell, J. C. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1750 · Cited by 555
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Park, B.-H., Hwang, T.-H., Liu, T., Sze, D. Y., Kim, J., Kwon, H., Oh, S. Y., Han, S., Yoon, J.-H., Hong, S. H., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70107-4 · Cited by 522
Self-citation
Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species soecificity
Symons, J. A., Alcamı́, A., & Smith, G. L. (1995) · Cell · doi:10.1016/0092-8674(95)90076-4 · Cited by 491
A soluble receptor for interleukin-1β encoded by vaccinia virus: A novel mechanism of virus modulation of the host response to infection
Alcamı́, A., & Smith, G. L. (1992) · Cell · doi:10.1016/0092-8674(92)90274-g · Cited by 478
Phase II Trial of Intratumoral Administration of ONYX-015, a Replication-Selective Adenovirus, in Patients With Refractory Head and Neck Cancer
Nemunaitis, J. J., Khuri, F. R., Ganly, I., Arseneau, J. C., Posner, M. R., Vokes, E. E., Kuhn, J. A., McCarty, T. M., Landers, S., Blackburn, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.289 · Cited by 470
Self-citation
An Orally Bioavailable Antipoxvirus Compound (ST-246) Inhibits Extracellular Virus Formation and Protects Mice from Lethal Orthopoxvirus Challenge
Yang, G., Pevear, D. C., Davies, M. H., Collett, M. S., Bailey, T., Rippen, S., Barone, L. R., Burns, C., Rhodes, G. R., Tohan, S., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.13139-13149.2005 · Cited by 466
From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage
Giordano, S., & Petrelli, A. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783503212 · Cited by 459
Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype
Buller, R. M. L., Smith, G. L., Cremer, K. J., Notkins, A. L., & Moss, B. (1985) · Nature · doi:10.1038/317813a0 · Cited by 453
Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins
Yu, Y., Shabahang, S., Timiryasova, T. M., Zhang, Q., Beltz, R. E., Gentschev, I., Goebel, W., & Szalay, A. A. (2004) · Nature Biotechnology · doi:10.1038/nbt937 · Cited by 424
Structure of vaccinia virus late promoters
Davison, A. J., & Moss, B. A. (1989) · Journal of Molecular Biology · doi:10.1016/0022-2836(89)90108-3 · Cited by 409
Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
Nemunaitis, J. J., Ganly, I., Khuri, F. R., Arseneau, J. C., Kuhn, J., McCarty, T. M., Landers, S., Maples, P. B., Romel, L., Randlev, B., et al. (2000) · PubMed · Cited by 402
Self-citation
Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression
Chakrabarti, S., Sisler, J. R., & Moss, B. A. (1997) · BioTechniques · doi:10.2144/97236st07 · Cited by 391
Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling
Colamonici, O. R., Domanski, P. J., Sweitzer, S. M., Larner, A. C., & Buller, R. M. L. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.27.15974 · Cited by 385
Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
McCart, J. A., Ward, J. M., Lee, J., Hu, Y., Alexander, H. R., Libutti, S. K., Moss, B., & Bartlett, D. L. (2001) · PubMed · Cited by 361
Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma
Mastrangelo, M. J., Maguire, H., Eisenlohr, L. C., Laughlin, C. E., Monken, C. E., McCue, P. A., Kovatich, A. J., & Lattime, E. C. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700066 · Cited by 353
Cancer gene therapy: fringe or cutting edge?
McCormick, F. P. (2001) · Nature reviews. Cancer · doi:10.1038/35101008 · Cited by 345
Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel
Halsell, J. S. (2003) · JAMA · doi:10.1001/jama.289.24.3283 · Cited by 333
Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA
Smith, G. L., & Moss, B. (1983) · Gene · doi:10.1016/0378-1119(83)90163-4 · Cited by 321
Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D., Wein, L. M., Andrews, J., Randlev, B., Heise, C. C., Uprichard, M. J., Hatfield, M. J., et al. (2002) · PubMed · Cited by 309
Self-citation
Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF
Kim, J. H., Oh, J. Y., Park, B. H., Lee, D. E., Kim, J. S., Park, H. E., Roh, M.-S., Je, J.-E., Yoon, J., Thorne, S. H., et al. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.05.008 · Cited by 303
Self-citation
Poxvirus pathogenesis
Buller, R. M. L., & Palumbo, G. J. (1991) · Microbiological Reviews · doi:10.1128/mr.55.1.80-122.1991 · Cited by 303
A triad of costimulatory molecules synergize to amplify T-cell activation.
Hodge, J. W., Sabzevari, H., Yafal, A. G., Gritz, L. R., Lorenz, M. G., & Schlom, J. (1999) · PubMed · Cited by 297
Poxvirus entry and membrane fusion
Moss, B. (2005) · Virology · doi:10.1016/j.virol.2005.09.037 · Cited by 288
Cidofovir in the treatment of poxvirus infections
Clercq, E. D. (2002) · Antiviral Research · doi:10.1016/s0166-3542(02)00008-6 · Cited by 286
Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow
Breitbach, C. J., Paterson, J. M., Lemay, C. G., Falls, T. J., McGuire, A., Parato, K. A., Stojdl, D. F., Daneshmand, M., Speth, K. A., Kirn, D. H., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300215 · Cited by 277
Self-citation
Synergistic Antitumor Effects of Immune Cell-Viral Biotherapy
Thorne, S. H., Negrin, R. S., & Contag, C. H. (2006) · Science · doi:10.1126/science.1121411 · Cited by 255
Self-citation
Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope
Vanderplasschen, A. F. C., Mathew, E., Hollinshead, M. S., Sim, R. B., & Smith, G. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7544 · Cited by 250
Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial
Reid, T. R., Galanis, E., Abbruzzese, J. L., Sze, D. Y., Andrews, J. C., Romel, L., Hatfield, M. J., Rubin, J., & Kirn, D. H. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301512 · Cited by 243
Self-citation
CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer
Ramesh, N., Ge, Y. C., Ennist, D. L., Zhu, M., Mina, M., Ganesh, S., Reddy, P. S., & Yu, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1059 · Cited by 243
Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers
Herbst, R. S., & Langer, C. J. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31525 · Cited by 242
Vaccinia virus immune evasion
Smith, G. L., Symons, J. A., Khanna, A., Vanderplasschen, A. F. C., & Alcamı́, A. (1997) · Immunological Reviews · doi:10.1111/j.1600-065x.1997.tb01012.x · Cited by 240
Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.
Mineta, T., Rabkin, S. D., & Martuza, R. L. (1994) · PubMed · Cited by 240
Spying on cancer
Gross, S., & Piwnica-Worms, D. R. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.12.011 · Cited by 238
Smallpox Vaccination and Adverse Reactions: Guidance for Clinicians
Cono, J., Casey, C., & Bell, D. M. (2003) · PsycEXTRA Dataset · doi:10.1037/e545972006-001 · Cited by 228
Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
Gulley, J. L., Arlen, P. M., Tsang, K.-Y., Yokokawa, J., Palena, C., Poole, D. J., Remondo, C., Cereda, V., Jones, J. L., Pazdur, M. P., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0126 · Cited by 228
Expansion of cytolytic CD8+ natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon γ production
Baker, J. B., Verneris, M. R., Ito, M., Shizuru, J. A., & Negrin, R. S. (2001) · Blood · doi:10.1182/blood.v97.10.2923 · Cited by 227
Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases
Reeves, P. M., Bommarius, B., Lebeis, S. L., McNulty, S., Christensen, J., Swimm, A. I., Chahroudi, A., Chavan, R., Feinberg, M. B., Veach, D. R., et al. (2005) · Nature Medicine · doi:10.1038/nm1265 · Cited by 226
Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC‐Pf7, a Pox‐Vectored, Multiantigen, Multistage Vaccine Candidate forPlasmodium falciparumMalaria
Ockenhouse, C. F., Sun, P., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K. E., Stoute, J. A., Magill, A., Krzych, U., Farley, L. S., et al. (1998) · The Journal of Infectious Diseases · doi:10.1086/515331 · Cited by 226
Eradication of Solid Human Breast Tumors in Nude Mice with an Intravenously Injected Light-Emitting Oncolytic Vaccinia Virus
Zhang, Q., Yu, Y., Wang, E., Chen, N. G., Danner, R. L., Munson, P. J., Marincola, F. M., & Szalay, A. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0146 · Cited by 224
The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma
Podar, K., Tonon, G., Sattler, M., Tai, Y., Gouill, S. L., Yasui, H., Ishitsuka, K., Kumar, S. K., Kumar, R., Pandite, L. N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609329103 · Cited by 218
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
Jäger, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., Ayyoub, M., Ritter, E., Ritter, G., Jäger, D., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606512103 · Cited by 216
Relaxin Expression From Tumor-Targeting Adenoviruses and Its Intratumoral Spread, Apoptosis Induction, and Efficacy
Kim, J.-H., Lee, Y.-S., Kim, H., Huang, J.-H., Yoon, A. R., & Yun, C. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj397 · Cited by 211
Vaccinia virus serpin B13R (SPI-2) inhibits interleukin-1beta-converting enzyme and protects virus-infected cells from TNF- and Fas-mediated apoptosis, but does not prevent IL-1beta-induced fever.
Kettle, S., Khanna, A., Alcam√≠, A., Jassoy, C., Ehret, R., & Smith, G. L. (1997) · Journal of General Virology · doi:10.1099/0022-1317-78-3-677 · Cited by 207
Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β
Zhu, J., Martinez, J., Huang, X., & Yang, Y. (2006) · Blood · doi:10.1182/blood-2006-06-027136 · Cited by 207
ONYX-015: Clinical data are encouraging
Kirn, D. H., Hermiston, T. W., & McCormick, F. P. (1998) · Nature Medicine · doi:10.1038/3902 · Cited by 205
Self-citation
Targeting of Interferon-Beta to Produce a Specific, Multi-Mechanistic Oncolytic Vaccinia Virus
Kirn, D. H., Wang, Y., Boeuf, F. L., Bell, J. C., & Thorne, S. H. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040353 · Cited by 204
Self-citation
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
Thorne, S. H., Hwang, T.-H., O’Gorman, W. E., Bartlett, D. L., Sei, S., Kanji, F., Brown, C. W., Werier, J. A., Cho, J.-H., Lee, D.-E., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32727 · Cited by 204
Self-citation
Why did p53 gene therapy fail in ovarian cancer?
Zeimet, A. G., & Marth, C. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01139-2 · Cited by 201
Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor
Wang, G., Barrett, J. W., Stanford, M. M., Werden, S. J., Johnston, J. B., Gao, X., Sun, M., Cheng, J. Q., & McFadden, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509341103 · Cited by 194
Carrier Cell-based Delivery of an Oncolytic Virus Circumvents Antiviral Immunity
Power, A., Wang, J., Falls, T. J., Paterson, J. M., Parato, K. A., Lichty, B. D., Stojdl, D. F., Forsyth, P. A., Atkins, H. L., & Bell, J. C. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300039 · Cited by 191
The Targeted Oncolytic Poxvirus JX-594 Demonstrates Antitumoral, Antivascular, and Anti-HBV Activities in Patients With Hepatocellular Carcinoma
Liu, T., Hwang, T.-H., Park, B.-H., Bell, J. C., & Kirn, D. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.143 · Cited by 189
Self-citation
Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery.
Wein, L. M., Wu, J. T. K., & Kirn, D. H. (2003) · PubMed · Cited by 188
Self-citation
Immunisation with canarypox virus expressing rabies glycoprotein
Cadoz, M., Meignier, B., Plotkin, S. A., Strady, A., Taylor, J., Tartaglia, J., & Paoletti, E. (1992) · The Lancet · doi:10.1016/0140-6736(92)92027-d · Cited by 182
Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier
Wang, F., Ma, Y., Barrett, J. W., Gao, X., Loh, J., Barton, E. S., Virgin, H. W., & McFadden, G. (2004) · Nature Immunology · doi:10.1038/ni1132 · Cited by 180
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen‐specific immunotherapy in patients with MUC1‐positive advanced cancer
Rochlitz, C. F., Figlin, R. A., Squiban, P. J., Salzberg, M. O., Pless, M., Herrmann, R., Tartour, É., Zhao, Y., Bizouarne, N., Baudin, M., et al. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.397 · Cited by 171
Adenovirus Biodistribution and Noninvasive Imaging of Gene Expression In Vivo by Positron Emission Tomography Using Human Sodium/Iodide Symporter as Reporter Gene
Groot-Wassink, T., Aboagye, E. O., Glaser, M., Lemoine, N. R., & Vassaux, G. (2002) · Human Gene Therapy · doi:10.1089/104303402760293565 · Cited by 165
Dissociation of progeny vaccinia virus from the cell membrane is regulated by a viral envelope glycoprotein: effect of a point mutation in the lectin homology domain of the A34R gene
Blasco, R., Sisler, J. R., & Moss, B. A. (1993) · Journal of Virology · doi:10.1128/jvi.67.6.3319-3325.1993 · Cited by 153
Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy
Wittek, R. (2006) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2005.12.001 · Cited by 151
Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccination
Pütz, M. M., Midgley, C. M., Law, M., & Smith, G. L. (2006) · Nature Medicine · doi:10.1038/nm1457 · Cited by 150
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells
Cole, C., Qiao, J., Kottke, T. J., Díaz, R. M., Ahmed, A. U., Sanchez-Perez, L. A., Brunn, G. J., Thompson, J., Chester, J. D., & Vile, R. G. (2005) · Nature Medicine · doi:10.1038/nm1297 · Cited by 148
Chemical control of protein stability and function in living mice
Banaszynski, L. A., Sellmyer, M. A., Contag, C. H., Wandless, T. J., & Thorne, S. H. (2008) · Nature Medicine · doi:10.1038/nm.1754 · Cited by 147
Self-citation
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin
Bell, E., Shamim, M., Whitbeck, J. C., Sfyroera, G., Lambris, J. D., & Isaacs, S. N. (2004) · Virology · doi:10.1016/j.virol.2004.05.004 · Cited by 137
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy
Qiao, J., Kottke, T. J., Willmon, C. L., Galivo, F., Wongthida, P., Díaz, R. M., Thompson, J., Ryno, P. K., Barber, G. N., Chester, J. D., et al. (2007) · Nature Medicine · doi:10.1038/nm1681 · Cited by 136
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction
Yang, H., Kim, S.-K., Kim, M., Reche, P. A., Morehead, T. J., Damon, I. K., Welsh, R. M., & Reinherz, E. L. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523220 · Cited by 134
Cell proliferative response to vaccinia virus is mediated by VGF
Buller, R. M. L., Chakrabarti, S., Moss, B., & Fredricksont, T. (1988) · Virology · doi:10.1016/0042-6822(88)90635-6 · Cited by 133
The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2
Guo, Z. S., Naik, A. M., O’Malley, M. E., Popovič, P., DeMarco, R., Hu, Y., Yin, X., Yang, S., Zeh, H. J., Moss, B., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1630 · Cited by 126
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies
Ong, H. T., Hasegawa, K., Dietz, A. B., Russell, S. J., & Peng, K.-W. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302880 · Cited by 125
Reovirus as a novel oncolytic agent
Norman, K. L., & Lee, P. W. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9871 · Cited by 124
Different regulation of thymidine kinase during the cell cycle of normal versus DNA tumor virus-transformed cells.
Hengstschläger, M., Knöfler, M., Müllner, E., Ogris, E., Wintersberger, E., & Wawra, E. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36723-6 · Cited by 123
Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction
Yang, H., Kim, S.-K., Kim, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23220 · Cited by 118
Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell Function
Panchanathan, V., Chaudhri, G., & Karupiah, G. (2006) · Journal of Virology · doi:10.1128/jvi.00115-06 · Cited by 118
Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network
Tzahar, E., Moyer, J. D., Waterman, H., Barbacci, E. G., Bao, J., Levkowitz, G., Shelly, M., Strano, S., Pinkas‐Kramarski, R., Pierce, J. H., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5948 · Cited by 116
Getting oncolytic virus therapies off the ground
Bell, J. C., Lichty, B. D., & Stojdl, D. F. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00170-3 · Cited by 109
Bioluminescence imaging of vaccinia virus: Effects of interferon on viral replication and spread
Luker, K. E., Hutchens, M. A., Schultz, T. L., Pekosz, A. S., & Luker, G. D. (2005) · Virology · doi:10.1016/j.virol.2005.06.049 · Cited by 108
Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus
Foloppe, J., Kintz, J., Futin, N., Findeli, A., Cordier, P., Schlesinger, Y., Hoffmann, C., Tosch, C., Balloul, J.-M., & Erbs, P. (2008) · Gene Therapy · doi:10.1038/gt.2008.82 · Cited by 103
Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus — poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans
Kanesa-thasan, N., Smucny, J. J., Hoke, C. H., Marks, D. H., Konishi, E., Kurane, I., Tang, D. B., Vaughn, D. W., Mason, P. W., & Shope, R. E. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00191-2 · Cited by 103
Use of Vaccinia Virus in the Treatment of Metastatic Malignant Melanoma
Hunter-Craig, I. D., Newton, K. A., Westbury, G., & Lacey, B. W. (1970) · BMJ · doi:10.1136/bmj.2.5708.512 · Cited by 99
A Mitogenic Signal Triggered at an Early Stage of Vaccinia Virus Infection
de Magalhães, J. C., Andrade, A. A., Silva, P. N. G., Sousa, L. P., Ropert, C., Ferreira, P. C. P., Kroon, E. G., Gazzinelli, R. T., & Bonjardim, C. A. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100183200 · Cited by 98
Clinical development of gene therapy for colorectal cancer
Kerr, R. S. (2003) · Nature reviews. Cancer · doi:10.1038/nrc1147 · Cited by 97
Virus combinations and chemotherapy for the treatment of human cancers.
Kumar, S., Gao, L., Yeagy, B. A., & Reid, T. R. (2008) · PubMed · Cited by 92
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression
McCart, J., Puhlmann, M., Lee, J. K., Hu, Y., Libutti, S. K., Alexander, H., & BARTLETT, D. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301237 · Cited by 92
Enhancing Poxvirus Oncolytic Effects through Increased Spread and Immune Evasion
Kirn, D. H., Wang, Y., Liang, W., Contag, C. H., & Thorne, S. H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6515 · Cited by 89
Self-citation
Vaccinia Virus Intermediate Stage Transcription Is Complemented by Ras-GTPase-activating Protein SH3 Domain-binding Protein (G3BP) and Cytoplasmic Activation/Proliferation-associated Protein (p137) Individually or as a Heterodimer
Katsafanas, G. C., & Moss, B. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m411033200 · Cited by 82
Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice.
Gnant, M., Puhlmann, M., Alexander, H. R., & Bartlett, D. L. (1999) · PubMed · Cited by 82
New developments in multitargeted therapy for patients with solid tumours
Tourneau, C. L., Faivre, S. J., & Raymond, É. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.003 · Cited by 78
Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging after Systemic Delivery Using 111In-Pentetreotide
McCart, J. A., Mehta, N., Scollard, D. A., Reilly, R. M., Carrasquillo, J. A., Tang, N., Deng, H., Miller, M. S., Xu, H. M., Libutti, S. K., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.06.158 · Cited by 76
Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene
Chalikonda, S., Kivlen, M. H., O’Malley, M. E., Dong, X., McCart, J. A., Gorry, M. C., Yin, X.-Y., Brown, C., Zeh, H. J., Guo, Z. S., et al. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701110 · Cited by 74
The Vaccinia Virus Protein F1L Interacts with Bim and Inhibits Activation of the Pro-apoptotic Protein Bax
Taylor, J. M., Quilty, D., Banadyga, L., & Barry, M. K. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607465200 · Cited by 74
Tumor-Specific Gene Delivery Using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases
Gnant, M., Noll, L. A., Irvine, K. R., Puhlmann, M., Terrill, R. E., Alexander, H. R., & Bartlett, D. L. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.20.1744 · Cited by 71
Oncolytic Virotherapy: Approaches to Tumor Targeting and Enhancing Antitumor Effects
Thorne, S. H., Hermiston, T. W., & Kirn, D. H. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.007 · Cited by 64
Self-citation
Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors.
Lee, S., Eisenlohr, L. C., McCue, P. A., Mastrangelo, M. J., & Lattime, E. C. (1994) · PubMed · Cited by 60
Cancer immunotherapy with natural killer cells
Herberman, R. B. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.33079 · Cited by 59
Reovirus: Viral Therapy for Cancer ‘as Nature Intended’
Comins, C., Heinemann, L., Harrington, K. J., Melcher, A. A., Bono, J. S. D., & Pandha, H. (2008) · Clinical Oncology · doi:10.1016/j.clon.2008.04.018 · Cited by 56
Vaccination of Prostate Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax)
Amato, R. J., Drury, N. L., Naylor, S., Jac, J., Saxena, S., Cao, A., Hernandez-McClain, J., & Harrop, R. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817deafd · Cited by 55
Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis
Negro, F., Samii, K., Rubbia‐Brandt, L., Quadri, R. A., Male, P.-J., Zarski, J., Baud, M., Giostra, E., Beris, P., & Hadengue, A. (2000) · Journal of Medical Virology · doi:10.1002/(sici)1096-9071(200001)60:1 · Cited by 55
Retargeting polymer‐coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer
Green, N. K., Morrison, J., Hale, S. J. M., Briggs, S. S., Stevenson, M., Šubr, V., Ulbrich, K., Chandler, L. A., Mautner, V., Seymour, L. W., et al. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1121 · Cited by 54
Selective Intratumoral Amplification of an Antiangiogenic Vector by an Oncolytic Virus Produces Enhanced Antivascular and Anti-tumor Efficacy
Thorne, S. H., Tam, B. Y. Y., Kirn, D. H., Contag, C. H., & Kuo, C. J. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.12.010 · Cited by 54
Self-citation
Poxviruses as vectors for cancer immunotherapy.
Kwak, H., Hörig, H., & Kaufman, H. L. (2003) · PubMed · Cited by 52
Immunotherapy of Malignant Melanoma With Vaccinia Virus
Roenigk, H. H. (1974) · Archives of Dermatology · doi:10.1001/archderm.1974.01630050014003 · Cited by 50
Stem Cells: The Real Culprits in Cancer?
Clarke, M. F., & Becker, M. W. (2006) · Scientific American · doi:10.1038/scientificamerican0706-52 · Cited by 47
Mutations in the Vaccinia Virus A33R and B5R Envelope Proteins That Enhance Release of Extracellular Virions and Eliminate Formation of Actin-Containing Microvilli without Preventing Tyrosine Phosphorylation of the A36R Protein
Katz, E., Ward, B. M., Weisberg, A. S., & Moss, B. (2003) · Journal of Virology · doi:10.1128/jvi.77.22.12266-12275.2003 · Cited by 45
Using in Vivo Bioluminescence Imaging to Shed Light on Cancer Biology
Thorne, S. H., & Contag, C. H. (2005) · Proceedings of the IEEE · doi:10.1109/jproc.2005.844261 · Cited by 44
Self-citation
Pox Viral Vaccine Approaches
Arlen, P. M., Kaufman, H. L., & DiPaola, R. S. (2005) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.09.006 · Cited by 40
Determinants Of Antibody Response After Recombinant Gp160 Boosting In Vaccinia-Naive Volunteers Primed With Gp160-Recombinant Vaccinia Virus
Graham, B. S., Gorse, G. J., Schwartz, D. H., Keefer, M. C., McElrath, M. J., Matthews, T. J., Wright, P. F., Belshe, R. B., Clements, M. L., Dolin, R., et al. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/170.4.782 · Cited by 40
Poxvirus vaccines for cancer and HIV therapy
Essajee, S. M., & Kaufman, H. L. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.4.575 · Cited by 38
THE EXPERIMENTAL LOCAL THERAPY OF CUTANEOUS METASTASES OF MALIGNANT MELANOBLASTOMAS WITH COW POX VACCINE OR COLCEMLD (DEMECOLCINE OE OMAINE)
Belisario, J. C., & Milton, G. W. (1961) · Australasian Journal of Dermatology · doi:10.1111/j.1440-0960.1961.tb01628.x · Cited by 34
Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization
Naito, T., Kaneko, Y., & Kozbor, D. (2006) · Journal of General Virology · doi:10.1099/vir.0.82216-0 · Cited by 31
Intralesional Vaccinia/GM-CSF Recombinant Virus in the Treatment of Metastatic Melanoma
Mastrangelo, M. J., Maguire, H. C., Jr., & Lattime, E. C. (2002) · Advances in experimental medicine and biology · doi:10.1007/0-306-46817-4_34 · Cited by 31
A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus
Yang, S., Guo, Z. S., O’Malley, M. E., Yin, X., Zeh, H. J., & Bartlett, D. L. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302914 · Cited by 29
Translation of Targeted Oncolytic Virotherapeutics from the Lab into the Clinic, and Back Again: A High-Value Iterative Loop
Liu, T., Hwang, T.-H., Bell, J. C., & Kirn, D. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.70 · Cited by 26
Self-citation
In Search of a Kinder, Gentler Vaccine
Enserink, M. (2002) · Science · doi:10.1126/science.296.5573.1594 · Cited by 21
Drug evaluation: Therion's rV-PSA-TRICOM + rF-PSA-TRICOM prime-boost prostate cancer vaccine.
Doehn, C., Kausch, I., Böhmer, T., Sommerauer, M., & Jocham, D. (2007) · PubMed · Cited by 9

Flagged first, then by citations

Research works printed but not linked: 2

Moss, B. in Field's Virology Ch. 84 (eds Fields, B. N., Knipe, D.M. & Howley, P. M.) (Lippincott-Raven, Philadelphia, 2001).
Burdick, K. H. Malignant melanoma treated with vaccinia injections. Arch. Dermatol. 82, 438–439 (1960).

Sorted by citations

Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
WICKI, A. N., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,962
Oncolytic virotherapy
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
Heo, J., Reid, T. R., Ruo, L., Breitbach, C. J., Rose, S. C., Bloomston, M., Cho, M., Lim, H. Y., Chung, H. C., Kim, C. W., et al. (2013) · Nature Medicine · doi:10.1038/nm.3089 · Cited by 781
Self-citation
Oncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 776
Oncolytic Viruses in Cancer Treatment
Lawler, S. E., Speranza, M. C., Cho, C., & Chiocca, E. A. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 617

See all 402

Authors: Kirn, D. H., & Thorne, S. H.
ORCID: Kirn, David H.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2009-01
Volume: 9
Issue: 1
Pages: 64-71
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc2545
OpenAlex: W2079647238
Cited by: 402
References: 134
Citations by year: 2026: 7 · 2025: 7 · 2024: 19 · 2023: 14 · 2022: 16 · 2021: 16 · 2020: 20 · 2019: 14 · 2018: 16 · 2017: 24 · 2016: 25 · 2015: 29 · 2014: 29 · 2013: 49 · 2012: 36
FWCI: 2.47
Type: journal article
Language: en
Open access: closed
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Bacterial Cancer Therapy
Keywords: vaccinia virus, cancer gene therapy, cancer vaccines, viral vectors
MeSH terms: Animals, Forecasting, Humans, Immunity, Cellular, Inflammation, Neoplasm Metastasis, Neoplasms, Poxviridae, Vaccinia virus, Virus Replication, Gene Expression Regulation, Viral, Cancer Vaccines, Oncolytic Virotherapy, Oncolytic Viruses, Mice, Host-Pathogen Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks